EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Value of adjuvant chemotherapy for patients with pT2N0M0 non‐small cell lung cancer receiving radical resection

Shiqi Chen, Siqian Yang, Yue Zhao, Yang Zhang, Qingyuan Huang, Haoxuan Wu iD, Hong Hu, Yihua Sun, Yawei Zhang, Jiaqing Xiang, Ting Ye, Haiquan Chen iD

Thoracic Cancer · 2024-01 · 15 (3) · 258-265

DOI: 10.1111/1759-7714.15192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 14.12.2023. Verfasst von Shiqi Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cooperation Project of Conquering Major Diseases in Xuhui District, National Natural Science Foundation of China, Shanghai Science and Technology Commission General Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Associations between adjuvant chemotherapy (ACT) and the improvement in survival for patients with pT2N0M0 non‐small cell lung cancer (NSCLC) who received R0 resection remain controversial. This study aimed to evaluate the value of ACT for patients with pT2N0M0 NSCLCs, and to identify the subgroups who could benefit from ACT.

Methods

Multivariable Cox proportional hazards regression models were used to estimate independent prognostic factors. High‐risk factor (HRF) included visceral pleural invasion (VPI), lymphovascular invasion (LVI) and poor differentiation/undifferentiated tumors.

Results

Of the 899 patients, 277 (30.8%) patients received ACT. More younger patients ( p < 0.001) and male patients ( p = 0.007) received ACT. With the increase of pathological tumor size ( p < 0.001) and the number of HRFs ( p < 0.001), there was a significant rise in the proportion of patients receiving ACT. For all patients, ACT could not improve recurrence‐free survival (RFS) ( p = 0.672) and overall survival (OS) ( p = 0.306). For patients with pathological stage IIA or radiological pure‐solid tumors, ACT could significantly improve the OS ( p = 0.011 and p = 0.037, respectively), and multivariate analysis revealed that ACT was an independent prognostic factor for patients with pathological stage IIA ( p = 0.005). ACT could improve the OS significantly in patients with pathological stage IB pure‐solid lung adenocarcinoma (LUAD) ( p = 0.043).

Conclusion

ACT was valuable for patients with pathological stage IIA (pT2bN0M0) and patients with radiological pure‐solid LUAD of pathological stage IB. A combination of radiological features and pathological subtypes could be helpful when selecting patients with pT2N0M0 NSCLCs for ACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdenocarcinoma of LungHumansMaleNeoplasm StagingPrognosisRetrospective StudiesNeoplasm InvasivenessChemotherapy, Adjuvant

Stichwörter der Autor:innen

adjuvant chemotherapynon-small cell lung cancerpT2N0M0radical resection

Autor:innen und Institutionen

  • Departments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Institute of Thoracic Oncology, Fudan University, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • School of Life Sciences, Fudan University, Shanghai, China.

ORCID-Profile: Haoxuan Wu, Haiquan Chen

Förderung

  • Cooperation Project of Conquering Major Diseases in Xuhui District
  • National Natural Science Foundation of China
  • Shanghai Science and Technology Commission General Project
  • Shanghai Science and Technology Innovation Action Project

Zitieren

APA

Chen, S., Yang, S., Zhao, Y., Zhang, Y., Huang, Q., Wu, H., Hu, H., Sun, Y., Zhang, Y., Xiang, J., Ye, T., & Chen, H. (2024). Value of adjuvant chemotherapy for patients with pT2N0M0 non‐small cell lung cancer receiving radical resection. Thoracic Cancer, 15(3), 258-265. https://doi.org/10.1111/1759-7714.15192

Vancouver

Chen S, Yang S, Zhao Y, Zhang Y, Huang Q, Wu H, et al. Value of adjuvant chemotherapy for patients with pT2N0M0 non‐small cell lung cancer receiving radical resection. Thoracic Cancer. 2024;15(3):258-265. doi:10.1111/1759-7714.15192

BibTeX
@article{Chen2024,
  author = {Chen, Shiqi and Yang, Siqian and Zhao, Yue and Zhang, Yang and Huang, Qingyuan and Wu, Haoxuan and Hu, Hong and Sun, Yihua and Zhang, Yawei and Xiang, Jiaqing and Ye, Ting and Chen, Haiquan},
  title = {Value of adjuvant chemotherapy for patients with pT2N0M0 non‐small cell lung cancer receiving radical resection},
  journal = {Thoracic Cancer},
  year = {2024},
  volume = {15},
  number = {3},
  pages = {258--265},
  doi = {10.1111/1759-7714.15192}
}
Kostenlos starten →